Gurobi 9.5 Delivers Enterprise Features and Even Better Performance
16.11.2021 17:00:00 EET | Business Wire | Press release
Gurobi Optimization, LLC, creator of the world’s fastest mathematical optimization solver, today announced the release of Gurobi Optimizer 9.5. This release provides customers with an even faster compute engine, with impressive performance improvements across all supported problem types.
Gurobi 9.5 also includes new features that make it well suited for enterprise use, including:
- Seamless Docker Deployments: Run Gurobi in container environments, easily, with the Gurobi Web License Service (WLS).
- User-Level Management: Manage users and assign permission levels in a centralized location, by integrating Gurobi Compute Server and Cluster Manager with LDAP repositories.
- Better API Key Management: Label API keys with descriptive information in the Cluster Manager to simplify API key tracking and management.
Customers will discover over a dozen enhancements across the product, such as native support for Apple M1, powerful new heuristics for non-convex quadratic models, norm constraints, deterministic work measures, memory limit parameters, and more user control of IIS computation, as well as improvements to callbacks and tuning.
“I’m confident that our customers will be really pleased with Gurobi 9.5. And happy customers are the foundation upon which our whole business is built,” said Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization.
Gurobi 9.5 also showcases the company’s continued support for Python—the most popular programming language in the world—with an improved Python interface and support for Python 3.10.
“One of the most challenging parts of running a modern business is managing complexity. Every decision you make affects other decisions. With Gurobi Optimizer, you can explore all the possibilities and all the implications—and identify your best course of action, in seconds,” added Dr. Rothberg.
“Even though the Gurobi Optimizer is the fastest mathematical optimizer in the world, we’re not going to rest on our laurels. We will keep pushing to improve and innovate because we’re passionate about mathematical optimization and the difference it makes in solving real-world problems,” said Dr. Tobias Achterberg, Vice President of Research and Development (R&D) at Gurobi Optimization.
The team’s commitment to continual improvement is evident in the performance numbers. Gurobi Optimizer 9.5 has boosted its speeds across the board, including:
- Primal Simplex: 23% faster overall, 43% faster on hard models
- Dual Simplex: 20% faster overall, 43% faster on hard models
- Barrier: 18% faster overall, 56% faster on hard models
- Concurrent LP: 14% faster overall, 54% faster on hard models
- MIP: 15% faster overall, 27% faster on hard models
- Convex MIQP: 30% faster overall, 68% faster on hard models
- Convex MIQCP: 33% faster overall, 78% faster on hard models
- Non-Convex MIQCP: 3.0x faster overall, 7.5x faster on hard models
“Our customers rely on us for solving extremely complex challenges. Our technology makes that possible. But our secret sauce is our team of specialists and PhDs, as well as our partner network. These are the people who make Gurobi come to life—working closely with our customers and helping them succeed,” added Dr. Achterberg.
To learn more about Gurobi 9.5, please visit https://www.gurobi.com/9.5.
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005125/en/
Contact information
Nell-Marie Colman
(540) 952 9719
Gurobi Optimization
colman@gurobi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom